Market Intelligence, Clinical Progress, and High-Purity Reagents for MMP Regulation, Organ Fibrosis, and Acute Kidney Injury Diagnostics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TIMP2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TIMP2 Recombinant Protein High purity (>95%), Endotoxin Controlled, Sequence Verified. HEK293 expressed for native conformation. |
View TIMP2 Products |
| Gene Delivery | TIMP2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View TIMP2 Products |
| Benchmark Ab | Anti-TIMP2 Recombinant Antibody High-affinity positive control for ELISA, Western Blot, and functional blocking. |
View TIMP2 Products |
| Validator | TIMP2 siRNA Set Target-specific knockdown verification in primary cells and cell lines. |
View TIMP2 Products |
| Related Target A | MMP2 Primary enzymatic target of TIMP2 inhibition; critical for invasion assays. |
View MMP2 Products |
| Related Target B | MMP14 (MT1-MMP) Membrane-bound metalloproteinase that forms a ternary complex with TIMP2 and pro-MMP2. |
View MMP14 Products |
| Related Target C | IGFBP7 Synergistic biomarker paired with TIMP2 for acute kidney injury (AKI) risk assessment. |
View IGFBP7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Differentiating TIMP2 inhibition of MMP2 vs. MT1-MMP activation | HEK293-expressed recombinant TIMP2 preserves native folding and post-translational modifications, ensuring physiological binding kinetics. |
| Cross-species ortholog validation | Human, Mouse, and Rat TIMP2 orthologs are available with >95% purity verified by SDS-PAGE. |
| Lack of reliable assay controls | Sequence-verified clinical benchmark antibodies and recombinant proteins included in the catalog. |
| Off-target assay interference | Endotoxin-controlled (<1.0 EU/μg) and mass spectrometry-verified proteins minimize assay background. |
Live TIMP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Tissue Inhibitor of Metalloproteinases 2 (TIMP2) is expanding beyond its traditional role as a matrix metalloproteinase (MMP) inhibitor. Current clinical pipelines leverage TIMP2 both as a highly sensitive biomarker for renal stress (specifically in acute kidney injury) and as a therapeutic target in oncology, tissue fibrosis, and cardiovascular remodeling. The dual nature of TIMP2—acting as an inhibitor of active MMPs while cooperatively facilitating the activation of pro-MMP2 via MMP14—requires highly specific molecular tools to dissect its contextual activity in disease microenvironments.
As next-generation biologics enter development, the focus is shifting toward monoclonal antibodies that can selectively block or mimic TIMP2 interactions with specific MMP subfamilies, avoiding systemic toxicity associated with broad-spectrum metalloproteinase inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Academic & Biopharma Consortia | Solid Tumors, Metastasis, Fibrosis | Epitope mapping and competitive binding assays requiring high-purity, natively glycosylated TIMP2 antigen. |
| Recombinant Proteins / Peptides | Renal & Cardiovascular Therapeutics | Ischemia-Reperfusion Injury, AKI | In vitro activity assays requiring endotoxin-free TIMP2 to evaluate cytoprotective and anti-inflammatory properties. |
| In Vitro Diagnostics (IVD) | Astute Medical, Ortho Clinical Diagnostics | Acute Kidney Injury (AKI) | High-purity, sequence-verified TIMP2 and IGFBP7 proteins for calibrator and control development. |